First in Cardiovascular Device Testing Revenue and Competitors

Victoria, BC CAN

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • First in Cardiovascular Device Testing's estimated annual revenue is currently $8.3M per year.(i)
  • First in Cardiovascular Device Testing's estimated revenue per employee is $251,000

Employee Data

  • First in Cardiovascular Device Testing has 33 Employees.(i)
  • First in Cardiovascular Device Testing grew their employee count by 6% last year.

First in Cardiovascular Device Testing's People

NameTitleEmail/Phone
1
Director Product DevelopmentReveal Email/Phone
2
Director MarketingReveal Email/Phone
3
Mechanical EngineerReveal Email/Phone
4
Business Development ManagerReveal Email/Phone
5
PresidentReveal Email/Phone
6
Software Engineering Co-opReveal Email/Phone
7
Quality Assurance SpecialistReveal Email/Phone
8
Technical Support EngineerReveal Email/Phone
9
Test EngineerReveal Email/Phone
10
Test EngineerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1M4-20%N/AN/A
#2
$16.6M66N/AN/AN/A
#3
$7M2817%N/AN/A
#4
$8.3M336%N/AN/A
#5
$6M249%N/AN/A
#6
$156.1M6226%N/AN/A
#7
$33.1M132-1%$11.3MN/A
#8
$56.2M224N/AN/AN/A
#9
$15.8M63-3%N/AN/A
#10
N/A0N/AN/AN/A
Add Company

What Is First in Cardiovascular Device Testing?

ViVitro Labs is a global provider of cardiovascular and endovascular device test equipment, laboratory testing, consulting and engineering services. Since 1975. ViVitro Labs Inc. offers industry-leading cardiovascular test equipment and related laboratory testing and consulting services. Hundreds of organizations in over 40 countries for 30+ years have trusted ViVitro expertise, accuracy, and quality for their heart valve, LVAD, TAH, stent, and graft testing. ViVitro Laboratory Services holds ISO/IEC 17025 accreditation based on ISO 5840. ViVitro products are manufactured by StarFish Medical in an ISO 13485:2003 certified manufacturing facility. ViVitro's A2LA Scope of Accreditation includes the physical and mechanical testing of heart valve substitutes. The ViVitro SuperPump is a digitally controlled, hydraulic piston pulsatile pump that creates physiological cardiac flows. The ViVitro Pulse Duplicator system is the world's most widely cited and most used in-vitro cardiovascular hydrodynamic testing system. The ViVitro HiCycle Durability Tester is used to determine the durability of replacement heart valves and other cardiac devices under physiological loading for R&D and regulatory submissions. The ViVitro Endovascular Simulator creates physiological pulsatile flow and pressures for testing many types of cardiovascular devices. It addresses requirements of ISO 5840, ISO 25539, and ISO 7198 standards as they include simulated use guidelines.

keywords:N/A

N/A

Total Funding

33

Number of Employees

$8.3M

Revenue (est)

6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

First in Cardiovascular Device Testing News

2022-04-17 - Abbott Beats Expectations, as Covid-19 Test Sales Provide Boost

Medical devices took a substantial hit early in the pandemic, as hospitals and patients canceled so-called elective procedures;...

2022-04-17 - Abbott reports $900M Q1 revenue beat on COVID-19 test ...

Abbott Laboratories on Wednesday reported first-quarter sales of $11.9 ... Abbott's global medical devices sales grew 11.5% on an organic...

2022-04-17 - Abbott beats The Street in Q1 as COVID-19 testing continues ...

Medical device revenues increased by 7.4% from the first quarter of 2021, with diabetes care (14.9% growth), heart failure (14.2%) and...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$6.5M330%N/A
#2
$3.8M3318%N/A
#3
$6.5M33-3%N/A
#4
$5.1M33N/AN/A
#5
N/A3310%N/A